Business Context and Reporting Period
This Form 8-K filing by Alector, Inc. (ALEC) is dated March 20, 2020. The report primarily addresses two events: the announcement of financial results for the quarter and year ended December 31, 2019, and the appointment of a new director to the Board.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the detailed financial results for the period ended December 31, 2019. However, the text of this 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes and Corporate Governance
On March 20, 2020, Dr. Paula Hammond was appointed to the Board of Directors and the Compensation Committee. Key details of this appointment include:
- Role: Class I director with a term expiring at the 2022 annual meeting.
- Background: David H. Koch Chair Professor of Engineering at MIT and Head of the Department of Chemical Engineering since 2016.
- Compensation: Annual cash compensation of $40,000 for Board service plus $5,000 for Compensation Committee service.
- Equity Grant: Automatic grant of an option to purchase 29,443 shares of common stock on March 20, 2020.
- Vesting Schedule: 25% vests on the one-year anniversary; the remainder vests monthly (1/48th) thereafter, contingent on continued service.
Guidance, Outlook, and Risks
The filing does not contain specific management commentary, forward-looking guidance, or risk factors within the text of the 8-K itself. The financial outlook and operational risks are contained within the referenced press release (Exhibit 99.1) regarding the 2019 results.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 24, 2020) for specific 2019 financial metrics (revenue, net loss, cash position).
- Verify the impact of the new director appointment on the Compensation Committee's composition and future executive compensation decisions.
- Confirm the vesting terms and dilution impact of the 29,443 share option granted to Dr. Hammond.
- Check for any subsequent updates regarding the company's cash runway given the biotech sector's capital-intensive nature.